Quantum-Si (NASDAQ:QSI) Insider Sells 15,111 Shares

Quantum-Si Incorporated (NASDAQ:QSI) insider John Vieceli sold 15,111 shares of the firm’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $0.96, for a total value of $14,506.56. Following the completion of the sale, the insider owned 1,155,546 shares in the company, valued at $1,109,324.16. The trade was a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Quantum-Si Stock Performance

Shares of QSI traded down $0.05 during midday trading on Wednesday, hitting $0.83. 5,042,480 shares of the stock traded hands, compared to its average volume of 6,078,957. The business’s 50 day moving average price is $0.99 and its two-hundred day moving average price is $1.04. The firm has a market capitalization of $180.13 million, a PE ratio of -1.62 and a beta of 3.18. Quantum-Si Incorporated has a 1-year low of $0.69 and a 1-year high of $3.10.

Quantum-Si (NASDAQ:QSI) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. The business had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.30 million. Quantum-Si had a negative net margin of 5,605.88% and a negative return on equity of 47.35%. As a group, equities research analysts forecast that Quantum-Si Incorporated will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Quantum-Si

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC acquired a new position in Quantum-Si during the 1st quarter valued at about $4,721,000. State Street Corp boosted its holdings in shares of Quantum-Si by 26.5% in the fourth quarter. State Street Corp now owns 3,562,721 shares of the company’s stock valued at $3,919,000 after acquiring an additional 745,231 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Quantum-Si in the third quarter valued at approximately $865,000. Bank of America Corp DE increased its stake in shares of Quantum-Si by 426.6% during the second quarter. Bank of America Corp DE now owns 465,999 shares of the company’s stock valued at $913,000 after acquiring an additional 377,504 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Quantum-Si by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 4,114,375 shares of the company’s stock valued at $4,527,000 after acquiring an additional 367,206 shares during the period. Institutional investors own 39.90% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on QSI. Canaccord Genuity Group cut their price target on Quantum-Si from $1.50 to $1.00 and set a “hold” rating on the stock in a report on Wednesday, March 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $1.00.

About Quantum-Si

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.